BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34640639)

  • 1.
    Bainrauch A; Šisl D; Markotić A; Ostojić A; Gašparov S; Bralić Lang V; Kovačić N; Grčević D; Mrzljak A; Kelava T
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].
    Bing H; Wang W; Li YL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):156-162. PubMed ID: 33685085
    [No Abstract]   [Full Text] [Related]  

  • 3. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
    Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
    Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
    Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
    Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
    Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma].
    Wang LQ; Guo WH; Guo ZW; Qin P; Zhang R; Zhu XM; Liu DW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1611-1616. PubMed ID: 30572387
    [No Abstract]   [Full Text] [Related]  

  • 8. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    Raksayot M; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Treeprasertsuk S; Poovorawan Y; Tanaka Y; Tangkijvanich P
    J Gastroenterol; 2019 May; 54(5):427-436. PubMed ID: 30506232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma.
    Yu T; Han C; Zhu G; Liao X; Qin W; Yang C; Liu Z; Su H; Liu X; Yu L; Liu Z; Lu S; Chen Z; Liang Y; Huang J; Qin X; Gui Y; Li J; Peng T
    Cancer Med; 2017 Jul; 6(7):1587-1600. PubMed ID: 28568708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNPLA3 rs738409 associates with alcoholic liver cirrhosis but not with serum levels of IL6, IL10, IL8 or CCL2 in the Russian population.
    Peregud DI; Baronets VY; Lobacheva AS; Ivanov AS; Arisheva OS; Garmash IV; Kobalava ZD; Pirozhkov SV; Terebilina NN
    Ann Hepatol; 2021; 20():100247. PubMed ID: 32871288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of genetic variants, genetic risk score and DNA methylation of PNPLA3 and TM6SF2 in alcohol liver cirrhosis.
    Shankarappa B; Mahadevan J; Murthy P; Purushottam M; Viswanath B; Jain S; Devarbhavi H; Mysore V A
    Indian J Gastroenterol; 2023 Dec; 42(6):800-807. PubMed ID: 37589914
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.
    Manchiero C; Nunes AKDS; Magri MC; Dantas BP; Mazza CC; Barone AA; Tengan FM
    BMC Infect Dis; 2017 Dec; 17(1):780. PubMed ID: 29258449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.
    Li JF; Zheng EQ; Xie M
    Gene; 2019 Feb; 685():143-148. PubMed ID: 30403964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Type 2 Diabetes in the Association of
    Gabriel-Medina P; Ferrer-Costa R; Rodriguez-Frias F; Ciudin A; Augustin S; Rivera-Esteban J; Pericàs JM; Selva DM
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
    Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
    Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.
    Falleti E; Fabris C; Cmet S; Cussigh A; Bitetto D; Fontanini E; Fornasiere E; Bignulin S; Fumolo E; Bignulin E; Pirisi M; Toniutto P
    Liver Int; 2011 Sep; 31(8):1137-43. PubMed ID: 21745286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population.
    Wang X; Liu Z; Wang K; Wang Z; Sun X; Zhong L; Deng G; Song G; Sun B; Peng Z; Liu W
    Front Genet; 2016; 7():140. PubMed ID: 27532011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.